Oxafence ProGear Selected for Vizient Innovative Technology Exchange

SEATTLE, Wash., July 27, 2026 — Singletto, Inc. and Prestige Ameritech have been selected to exhibit the ProGear® ASTM Mask with Oxafence® Active Protection™ at the Vizient® Innovative Technology Exchange. The FDA-cleared ASTM Level 3 mask continuously inactivates 99.9% of tested viruses on the mask surface within 5 minutes*. Vizient, the nation's largest provider-driven healthcare performance improvement company, will hold the Exchange on Sept. 24 in Las Vegas.

The annual Innovative Technology Exchange offers selected suppliers the unique opportunity to demonstrate their product or service to supply chain and clinical leaders from Vizient’s hospital clients and subject matter experts who serve on their supply councils. Each product or service will showcase how it improves clinical outcomes, enhances safety or drives incremental improvements to healthcare delivery or business models.

Face masks are among healthcare's most essential and widely used forms of personal protective equipment, yet they have remained largely unchanged for decades. Manufactured in the United States by Prestige Ameritech, the ProGear Mask with Oxafence Active Protection combines ASTM Level 3 barrier protection with virus-inactivating features enabled by Oxafence technology, which continuously inactivates tested viruses on the outer mask surface.

The Oxafence ProGear ASTM Level 3 Mask is the first commercial product powered by Oxafence, Singletto's active technology platform. Beyond masks, the company partners with manufacturers of personal protective equipment, textiles, and other healthcare products to incorporate Oxafence® Active Protection ™ into existing products and manufacturing processes.

"Healthcare has made remarkable advances in diagnostics, therapeutics, and medical devices, yet one of its most frequently used and essential products has seen comparatively little innovation," said John Bjornson, CEO and Co-Founder of Singletto. "We believed face masks represented one of the greatest opportunities to demonstrate how active protection technologies can be integrated into everyday healthcare products. We're honored to present that first commercial demonstration at the Vizient Innovative Technology Exchange and look forward to discussing how active protection technologies may help shape the next generation of healthcare products."

"I've spent more than 50 years designing and manufacturing masks, and I've always hoped to see the day when masks could do more than simply filter viruses – they could actively inactivate them," said Dan Reese, Chief Executive Officer of Prestige Ameritech. "I've met with countless companies over the years pursuing that vision, but Oxafence stood apart. We believed Oxafence had the potential to meaningfully advance one of healthcare's most important products."

 “The evaluation process for medical device and supply companies selected to exhibit at the Exchange is highly rigorous,” said Kelly Flaharty, associate vice president of contract operations, Vizient. “Participation is a signal to healthcare providers that a product or service is being considered for an Innovative Technology contract.”

The annual Innovative Technology Exchange is part of Vizient's Innovative Technology Program that includes product review of supplier-submitted technologies by provider-led councils. Since 2003, Vizient has reviewed over 1,700 product submissions as part of its Innovative Technology Program.

About Singletto

Singletto develops and licenses Oxafence Active Protection™, a materials-applied ingredient technology designed for integration into existing products and manufacturing processes. The company’s focus is on enabling new functionality in existing materials, not on manufacturing end products. Singletto works with research, manufacturing, and distribution partners across healthcare, operational, and emerging application areas where traditional antimicrobial approaches have struggled to scale.

About Prestige Ameritech

Prestige Ameritech is America's largest domestic manufacturer of ASTM masks and one of the nation's leading manufacturers of NIOSH-approved N95 respirators. Founded in 2005 and headquartered in North Richland Hills, Texas, the company is TERO-certified and manufactures high-quality medical masks and respirators in the United States.

FDA-Cleared Indications for Use (excerpt)

* The ProGear Surgical Mask with Oxafence inactivates single isolates of the following test viruses after five minutes of contact with the treated surface of the face mask in laboratory (in vitro) tests under a lighting intensity of 500 ± 25 lux: Influenza A/PR/8/34/H1N1 (TC adapted, ATCC VR-1469), 3 log or 99.9% inactivation; Betacoronavirus 1 OC43 (ATCC VR-1558), 4 log or 99.99% inactivation; Feline Calicivirus F-9 (ATCC VR- 782), 4 log or 99.99% inactivation. Antiviral efficacy on other viruses has not been evaluated. Correlations between in vitro testing results and any clinical event have not been evaluated.